• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2012 Product Image

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2012

  • Published: October 2012
  • 59 pages
  • Global Markets Direct

Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome). Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Interstitial Cystitis (Painful Bladder Syndrome) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) 8
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics under Development by Companies 10
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Products under Development by Companies 17
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics Development 19
Astellas Pharma Inc. 19
Urigen Pharmaceuticals, Inc. 20
Plethora Solutions Holdings plc 21
Aquinox Pharmaceuticals Inc. 22
Trillium Therapeutics Inc. 23
Afferent Pharmaceuticals, Inc. 24
Interstitial Cystitis (Painful Bladder Syndrome) – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
ASP-3652 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
URG-101 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
lidocaine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TTI-1612 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CR-3465 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ProtoCure Intravesical Instillation Solution - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AF-219 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Heparin + Lidocaine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
amitriptyline - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AQX-1125 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
lidocaine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
omalizumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
LP-08 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Botulinum Toxin Type A - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Drug Profile Updates 49
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Discontinued Products 52
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics - Dormant Products 53
Interstitial Cystitis (Painful Bladder Syndrome) – Product Development Milestones 54
Featured News & Press Releases 54
Mar 28, 2012: Trillium Doses First Patient In Phase I Clinical Trial Of TTI-1612 In Interstitial Cystitis 54
Dec 15, 2011: Trillium To Commence Clinical Testing Of TTI-1612 In Patients With Interstitial Cystitis/Bladder Pain Syndrome 54
Nov 30, 2011: TARIS Initiates Phase II Clinical Study With LiRIS In Interstitial Cystitis Patients 55
Jun 30, 2011: Urigen Provides Development Update For URG101 55
Mar 09, 2011: TARIS Initiates Clinical Study In Interstitial Cystitis Patients 55
Aug 18, 2010: Urigen Reports Type C Meeting With FDA For URG101 56
Aug 11, 2010: Urigen Announces FDA Follow Up For URG101 Program For Treatment Of Interstitial Cystitis 56
Apr 23, 2010: Urigen Files Request For FDA Meeting 56
Dec 29, 2008: Urigen Amends Its Core UCSD License For URG101 57
Aug 20, 2008: Urigen Announces Issuance Of Key Patent To URG101 For Interstitial Cystitis 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products Under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2012 8
Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Astellas Pharma Inc., H2 2012 19
Urigen Pharmaceuticals, Inc., H2 2012 20
Plethora Solutions Holdings plc, H2 2012 21
Aquinox Pharmaceuticals Inc., H2 2012 22
Trillium Therapeutics Inc., H2 2012 23
Afferent Pharmaceuticals, Inc., H2 2012 24
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 30
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Drug Profile Updates 49
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Discontinued Products 52
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics – Dormant Products 53

List of Figures
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2012 8
Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Route of Administration, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Molecule Type, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 30

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos